Q-omics provides the consensus-scored XPO7 profile across patient tissues and cancer cell-line models. XPO7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, XPO7 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, XPO7 RNA expression shows 20,434 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where XPO7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XPO7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XPO7 survival associations across molecular data types. XPO7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XPO7 RNA expression–survival associations across cancer types. High XPO7 expression shows unfavorable associations in MESO, LIHC and BLCA, but favorable associations in HNSC, KIRC and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for XPO7 RNA expression.
This table summarizes XPO7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for XPO7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XPO7 shows lower tumor expression in KIRC and higher tumor expression in HNSC, STAD, BLCA, LUSC and CHOL. The HNSC box plot shows higher XPO7 RNA expression in tumor versus normal tissue (log2 FC = +0.569, t-test p < 0.001).
This table shows molecular features associated with XPO7 in patient tissues and cancer cell lines. In patient samples, XPO7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, XPO7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
